---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015552"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:50:56.421925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q2 net loss $48.5M; VAX-24 Phase 2 fully enrolled with topline data expected Oct/Nov 2022

## Summary
- Cash, equivalents and investments of $361.4M at June 30, 2022 (vs. $273.1M at Dec. 31, 2021).
- R&D expenses $38.5M, up from $17.7M YoY due to VAX-24/VAX-XP/Phase 3 readiness activities.
- Net loss $48.5M for Q2 2022 compared to $23.7M in Q2 2021.
- Completed enrolment of Phase 2 portion of VAX-24 proof-of-concept study in adults 50-64 (≈800 subjects).
- FDA granted Fast Track designation for VAX-24 in adults; topline results expected Oct or Nov 2022.

## SEC filing metadata
- accession: 0000950170-22-015552
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000095017022015552/0000950170-22-015552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000095017022015552/pcvx-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015552
- JSON: https://secwatch.observer/filing/0000950170-22-015552.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015552.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.